Abivax stock rebounds 2.5% but remains oversold ahead of results
The Parisian biotech company signs a rebound at the end of the session, while the market as a whole advances and the publication of its half-yearly results approaches. The day was nevertheless eventful, with a dip below the support level followed by a recovery.
A breach of the 90.45 € support during the session before a clear technical rebound
Abivax touched a low of 89.45 € during the session, briefly breaching its support at 90.45 €, before recovering to trade at 92.70 € as the close approached, representing a gain of 2.49 % for the day. This rebound from the day's lows is notable, but it is not sufficient to erase the accumulated pressure on the stock over recent weeks. The RSI at 29 indicates a clear oversold configuration, consistent with a decline of nearly 10 % over one month and 8.4 % over the week.
The price remains below its three moving averages: the 20-day MA at 98.97 €, the 50-day MA at 107.29 € and the 200-day MA at 102.81 €, which places the stock outside any short-term upward momentum. The resistance level to overcome in order to initiate a significant recovery stands at 114.10 €, still approximately 23 % above the current price.
Short positions still significant ahead of half-yearly results expected on September 21
The 2026 half-yearly results for Abivax are expected on September 21, which places this event four days from the current close. This timeline gives particular significance to today's rebound, occurring during a period of high uncertainty for the stock. Furthermore, according to recorded statements, five funds cumulate 5.86 % of capital sold short, down 1.09 percentage points over thirty days (compared with 6.95 % one month ago). This level remains significant: a substantial portion of the capital is positioned bearishly, although the recent trend shows a gradual reduction of these positions.
This is no indication of the stock's future direction, but signals that institutional players are maintaining a short exposure ahead of the results publication. The stock is also advancing in a favorable market context, with the SBF 120 gaining 0.57 % during the session. The publication on September 21 will represent the next concrete test for valuation.
